IL-17A Increases Multiple Myeloma Cell Viability by Positively Regulating Syk Expression

Shunye Wang1, Yanan Ma1, Xudong Wang, Jie Jiang, Chenglu Zhang, Xinfeng Wang, Yijing Jiang, Hongming Huang2 and Liu Hong2

Department of Hematology, Affiliated Hospital of Nantong University, 20, xisi road, Nantong City, Jiangsu Province, 226001, China

Abstract

PURPOSE: Elevated IL-17 produced by Th17 cells was reported to promote myeloma cell growth and inhibit immune function in multiple myeloma (MM). IL-17A was also reported to promote MM growth through IL-17 receptors and enhance adhesion to bone marrow stromal cells (BMSCs). Spleen tyrosine kinase (Syk) influences MM cell survival and migration. Herein we aimed to investigate whether Syk was involved in the regulative role of IL-17A in the viability of MM cells.

METHODS: Cell viability was determined using CCK8 assay. The production of cytokine including IL-17A was evaluated with ELISA. Western blotting assay was used to determine protein expression levels of Syk and nuclear factor κB (NF-κB) related molecules. mRNA expression level of RORγt was detected with reverse transcription quantitative polymerase chain reaction. RESULTS: IL-17A was highly expressed in MM patients and was able to induce MM cell viability. Following analysis indicated that the effects of IL-17A were mediated by Syk/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. Immunoprecipitation also indicated that Syk is involved in IL-17A-induced Act1-TRAF6 complex formation and TRAF6 polyubiquitination in MM cells.

CONCLUSIONS: Taken together, our study indicated that IL-17A increases MM cell viability through activating NF-κB signal pathway via positively regulating Syk expression. Syk also participates in the formation of IL-17R-proximal signaling complex (IL-17R-Act1-TRAF6), which is essential for IL-17A-mediated NF-κB activation. These investigations highlight that inhibition of Syk may be a potential therapeutic option for neoplastic diseases such as MM.

Translational Oncology (2019) 12, 1086–1091

Introduction

Multiple myeloma (MM) is a malignant plasma cell (PC) disorder characterized by proliferation of malignant plasma cells in bone marrow [1]. A hallmark of MM is the presence of interplay between PC and bone marrow microenvironment [2]. Microenvironment is a complex system that causes functional damage of host immune system [3]. The host immune system and the bone marrow microenvironment play an essential role in the PC survival, apoptosis, migration/invasion, and drug resistance [4]. Abnormalities of T cell number or function have been observed in patients with MM [5]. CD4 helper T lymphocytes are critical in both antibody-mediated and cell-mediated immune responses [6]. T-helper 17 (TH17) cells, a subset of CD4 T cells, produce IL-17 and IL-22 under the polarization condition of interleukin-1(IL-1), IL-23,IL-6, and IL-21and with or without transforming growth factor-beta (TGF-β) [7]. Highly expressed TGF-β and IL-6 in myeloma patients enhance the generation of TH17 cells [8]. IL-17A is a prototypic member of the IL-17 family and mediate the expression of various chemokines and cytokines such as granulocyte-colony stimulating factor (GM-CSF), IL-6, TGF-β, and intercellular adhesion molecule-1 in a variety of cell...
IL-17A is dramatically upregulated in blood and bone marrow in MM and enhances MM cell proliferation through IL-17 receptor [10]. IL-17A has also been reported to play an important role in bone disease development in myeloma by regulating osteoclast formation and activation [11]. These results revealed the important role of IL-17A in the progression and development of MM.

Spleen tyrosine kinase (Syk), which belongs to the Src family, is a cytosolic nonreceptor protein tyrosine kinase (PTK) involved in various biological functions [12]. Syk is mainly expressed in hematopoietic cells including B cells, monocytes, and macrophages, thereby modulating the immune responses [12]. Syk was served as an essential component in the BCR signaling pathway, Fc receptors, and adhesion receptors [13]. Activation of Syk plays an important role in proinflammatory cytokine-induced nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation in airway epithelial cells [14,15]. Studies have shown that MM cells express Syk and p-Syk and interfere with Syk expression, effectively inhibiting the proliferation, migration, and survival of MM cells [16]. Another study found that incubation of MM cells with Syk inhibitors and primary MM cells resulted in increased cell proliferation and decreased migration, as well as dose-dependent inhibition of NF-κB and mitogen-activate d protein kinase (MAPK) signaling pathways [17]. Importantly, targeting Syk might be a promising therapeutic method for MM that is more efficient when combined with MAPK inhibitors [18]. These investigations suggested the promising role of Syk in MM.

Particularly, a recent research showed that, in human keratinocytes, IL-17R–proximal signaling complex is pivotal for IL-17A–stimulated NF-κB activation. Syk mediates the complex formation and tumor necrosis factor receptor–associated factor 6 (TRAF6) polyubiquitination [19]. Another study suggested that IL-17A triggers gene expression and protein secretion through the Syk-dependent NF-κB mechanism [20]. Based on these foundations, we aimed to investigate whether Syk was involved in the regulative role of IL-17A in the viability of MM cells.

**Materials and Methods**

**Cell Culture and Transient Transfection**

Human MM cell lines NCI-H929 and U226 were obtained from Cell Library, China Academy of Science, and Bioleaf Biotech (Shanghai, China). Cells were cultured in RPMI 1640 (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (Gibco-BRL, Grand Island, NY). Human bone marrow stromal cell line HS-5 (Cell Library, China Academy of Science) was cultured in DMEM (Sigma-Aldrich, St. Louis, MO) with 10% fetal bovine serum at 37°C in a 5% CO₂ incubator. Three siRNA sequences targeting Syk were designed and transfected into cells with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions.

**Western Blot Analysis and Antibodies**

The proteins were loaded to sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) gels followed by transferring onto polyvinylidene difluoride (PVDF) filter membranes (Millipore, Bedford, MA). The membranes were incubated with the primary antibodies against Iκκ (1:1000), IκBα (1:1000), TRAF6 (1:1000), Syk (1:1000), GAPDH (1:1000), p-Iκκ (1:1000), p-IκBα (1:1000), and horseradish peroxidase–conjugated secondary antibody for 2 hours at room temperature. All antibodies used were purchased from Cell Signalng Technology Danvers. The membranes were scanned by the ECL detection system. The band density was quantified using the Image J analysis system (Wayne Rasband, National Institutes of Health, Bethesda, MD). The experiments were carried out on three separate occasions.

**Cell Viability Assay**

MM cells at the density of 1×10⁵ were seeded into a 96-well plate (Corning Inc., Corning, NY) and incubated for 48 hours with or without IL-7A treatment. The cells were treated with 10 μl Cell Counting Kit-8 (CCK8) reagents (Dojindo, Kumamoto, Japan) for an additional 1 hour at 37°C in the dark. The absorbance was measured in a microplate reader (Bio-Rad, Hercules, CA) at a test wavelength of 450 nm.

**Co-Immunoprecipitation Assay**

The cells were collected and lysed with lysis buffer for 0.5-3 hours at 4°C. The supernatants were precleared with 30 μl protein A/G at 4°C for 1 hour. Then, 30 μl of supernatants served as input, and the rest of the supernatants were allocated into two parts and incubated with the Syk antibody and IgG at 4°C overnight. The samples were incubated with 30 μl protein A/G at 4°C for 2 hours. Finally, the precipitates were collected and washed three times and boiled for 10 minutes with SDS sample buffer followed by Western blot.

**Quantitative PCR**

Total RNA was extracted with RNeasy kit according to the manufacturer’s instructions (QIAGEN). Reverse transcription of RNA to cDNA was performed with the RETRO script kit (Ambion) according to the manufacturer’s protocol. Quantitative real-time reverse-transcriptase polymerase chain reaction (qRT-PCR) was carried out using the Applied Biosystems 7500 apparatus with the SYBR Green PCR master mix (Applied Biosystems) according to manufacturer’s instructions. The specific primers for human RORγt mRNA were as follows 5’-GCT GTTAG GAT GTG CCG-3’ and reverse primer 5’-GGATGC TT TGC GAT GA-3’.

**Statistical Analysis**

Data are presented as means ± SD. Each experiment was repeated at least three times using the Statistical Package for the Social Science SPSS 20.0 software (SPSS Inc., An IBM Company, Chicago, IL). The probability of .05 or less was considered statistically significant.

**Results**

**Elevated Levels of Th17 Cells and IL-17A Cytokine in MM Patients**

We firstly determined the frequency of Th17 cells in bone marrow tissues and peripheral blood in MM and control groups. The orphan nuclear receptor RORγt is the specific transcription factor of Th17 cells and is necessary for the generation of TH17 cells [21]. Results from qRT-PCR showed that the mRNA expression levels of RORγt in both bone marrow tissues and peripheral blood from MM patients were significantly higher than that from normal controls (P < .05; Figure 1A). We further analyzed the protein level of proinflammatory cytokine IL-17A secreted by Th17 cells in bone marrow tissues and peripheral blood by ELISA, respectively. Remarkable increase in the level of IL-17A was found in bone marrow tissues from MM patients compared with those from healthy controls (25.990 vs. 22.880 pg/ml; P < .05; Figure 1B). Consistently, significant upregulation of serum IL-17A from MM group compared with control group was also observed (131.056 vs. 9.900 pg/ml; P < .05; Figure 1C).
IL-17A Increases Viability of MM Cells Through Regulating Syk Expression

Next, the effect of IL-17A on viability of MM cell lines H929 and U266 was examined in vitro. A ss h o w ni nFigure 2 A, exogenous IL-17 significantly promoted viability of MM cell lines H929 and U266, as assessed by CCK8 assay in a time- and dose-dependent manner (\( P < .05 \)). To assess whether Syk was involved in IL-17A–induced enhancement in the viability of MM cells, the protein expression of Sykin response to IL-17A (150 ng/ml) stimuli was detected at different time points. Western blotting analysis showed that IL-17A treatment upregulated Syk expression in H929 and U266 cell lines in a time-dependent manner (\( P < .05 \); Figure 2 B). To further explore the underlying mechanism, Syk was knocked down by specific small interfering RNA (siSyk) and transfected into H929 and U266 cell lines treated with exogenous IL-17 (150 ng/ml). The silencing efficiency of siRNA was confirmed (Figure 2 C). Importantly, the increased MM cell viability upon IL-17A treatment was prevented by Syk silencing in a time-dependent manner (\( P < .05 \); Figure 2 C). Collectively, Syk was involved in IL-17A–induced enhancement in the viability of MM cells.

IL-17A Activates NF-κB Signaling Pathway via Positively Regulating Syk in MM Cells

Since NF-kB plays an important role in regulating MM cell viability, we speculated that IL-17A/Syk–induced cell proliferation might be associated with NF-kB signaling. As shown in Figure 3, A and B, IL-17A stimuli resulted in the phosphorylation of IKK and

---

**Figure 2.** IL-17A increases viability of MM cells through regulating Syk expression. (A) IL17A promoted the viability of MM cells. H292 cells and U266 cells were incubated with IL-17A at concentrations of 50, 100, and 150 ng/ml for 24, 48, and 72 hours, respectively. Cell viability was evaluated by CCK8 assay. (B) The protein expression of p-Syk and total Syk is detected in H292 cells and U266 cells treated with 150 ng/ml of IL-17A for 15 and 30 minutes using Western blot. (C) The protein expression of p-Syk and total Syk is detected in H292 cells and U266 cells, which were transfected with negative control small interfering RNA (NC) or siSyk and then treated with IL-17A at concentration of 150 ng/ml. (D) The cell viability was detected in H292 cells and U266 cells, which were transfected with siSyk or NC for 24 hours and then treated with IL-17A at concentration of 150 ng/ml for 24, 48, and 72 hours. Cell viability was evaluated by CCK8 assay. **"""""" denotes \( P < .05 \), **"""""" denotes \( P < .01 \), and **"""""" denotes \( P < .001 \) Data are expressed as the mean ± SD.
Syk knockdown significantly blocked the binding between TRAF6 and Act1, suggesting that Syk is involved in the proximal signalosome complex formation in MM cells. We found that IL-17 treatment was able to time-dependently increase the TRAF6 ubiquitination, while fostamatinib abolished the effect of IL-17 on TRAF6 ubiquitination (Figure 4B). Taken together, IL-17A–induced Act1-TRAF6 binding and TRAF6 polyubiquitination were mediated by Syk in MM cells.

**Discussion**

MM is a malignant plasma cell proliferative disease, accounting for about 10% of hematologic malignancies [22]. Abnormal immune cells and cytokines are important components of myeloma microenvironment and play an important role in the development of tumors [23]. Th17 cells are a newly discovered T cell subpopulation that secretes IL-17 and is involved in the development of various tumors and...
autoimmune diseases [24]. Th17 cells are considered as therapeutic targets for serious tumors and autoimmune diseases [25].

In view of the important role of immune cells in MM microenvironment, it is necessary to study the abnormal expression and mechanism of Th17 cells and IL-17A in MM. Further study revealed that IL-17A could promote MM cell viability. The underlying mechanism was subsequently explored. It is found that TRAF6 is highly expressed in myeloma cells and known to regulate the downstream NF-\(\kappa\)B signaling pathways and participates in the proliferation and apoptosis of myeloma cells [26]. NF-\(\kappa\)B is a pivotal regulator of the immune system and is involved in a variety of neoplastic diseases, which is known to be involved in IL-17A stimulation [27]. Consistently, in our study, we found that IL-17A activated the NF-\(\kappa\)B signaling pathway and enhanced TRAF6 ubiquitination. It raises the possibility that the promotive effects of IL-17A on MM cells may be associated with NF-\(\kappa\)B signaling pathway.

Syk, as a nonreceptor tyrosine kinase, is widely expressed in hematopoietic cells; plays a central role in B cell or T cell proliferation, differentiation, and survival; and is involved in innate immune and acquired immune responses [17]. Syk inhibitors are also used to treat a variety of autoimmune diseases (such as rheumatoid arthritis, asthma, allergic rhinitis) and have entered clinical trials [29]. Recent study identified Syk as a new therapeutic target because Syk inhibitors effectively inhibit MM cell proliferation through NF-\(\kappa\)B signaling pathway [28]. In this study, IL-17A could induce Syk phosphorylation, and the increased MM cell viability upon IL-17A treatment was prevented by Syk silencing in a time-dependent manner, demonstrating that Syk was involved in IL-17A–induced enhancement in the viability of MM cells. IL-17A could also induce the phosphorylation of Syk, IKK, and I\(\kappa\)B\(\alpha\). Besides, IL-17A stimulated the interaction between Syk and TRAF6. In addition, silencing of Syk attenuated IL-17A–induced NF-\(\kappa\)B activity. These results indicated that Syk is an upstream molecular of NF-\(\kappa\)B signaling pathway and acts on IL-17R-Akt1-TRAF6 complex.

TRAF6 is a tumor necrosis factor (TNF) superfamily and Toll-like / interleukin-1 receptor (Toll / IL-1) superfamily co-linker molecule that is important for intracellular signaling pathways [30]. Consistent with our results, previous studies have shown that Syk can be recruited to TRAF6 / Act1 or TRAF6 / TAK1 complexes in IL-17R signaling, and Syk may be a common regulator of TRAF6-dependent signaling pathways, with specific mechanisms of action depending on IL-17A stimulation [14]. However, the involvement of Syk in IL-17R signaling has not yet been fully understood. These results indicated that Syk plays an important role in positively regulating IL-17A–mediated TRAF6 signaling and cellular function. In this study, although we clearly observed that IL-17A enhances the interaction between Syk and TRAF6, whether Syk specifically modulates the molecular mechanism underlying the ubiquitination of the K63 locus of TRAF6 requires further validation. Detecting the ubiquitination alterations in the K63 locus of TRAF6 and ubiquitination after interfering with Syk gene expression is necessary. Moreover, we suspect that Syk may be recruited to the TRAF6 signal complex, but the specific mechanisms in MM need further study.

In conclusion, we showed that Syk is an important molecule in the IL-17A–mediated NF-\(\kappa\)B signaling pathway. The results demonstrated that IL-17A increases Syk expression, which regulates the ubiquitination of TRAF6, affects the downstream NF-\(\kappa\)B signaling pathway, and consequently results in the enhanced MM cell viability. This study provides a better understanding of IL-17A–mediated signaling pathways but also provide potential therapeutic target for MM.

Acknowledgement
This work was funded by the National Natural Science Foundation of China (grant no. 81201857), the Science and Technology Project...
of Nantong City (grant no. MS12016012), and the Nantong Science and Technology Program (grant no. MS22015055).

Conflict of Interest
The authors declare that there is no conflict of interest.

References

[1] Palumbo A and Anderson K (2011). Multiple myeloma. *N Engl J Med* **364**, 1046–1060.
[2] Abe M (2011). Targeting the interplay between myeloma cells and the bone marrow microenvironment. *Int J Hematol* **94**, 334–343.
[3] Romano A, Conticello C, Cavalli M, Vetro C, La Fauci A, and Partinelli NL, et al (2014). Immunological dysregulation in multiple myeloma microenvironment. *Biomed Res Int* **2014**198539.
[4] Landgren O and Korde N (2011). Multiple myeloma precursor disease: current clinical and epidemiological insights and future opportunities. *Oncology (Williston Park)* **25**, 589–596.
[5] Munshi NC (1997). Immunoregulatory mechanisms in multiple myeloma. *Hematol Oncol Clin North Am* **11**, 51–69.
[6] Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, and Coffman RL (1986). Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. *J Immunol* **136**, 2348–2357.
[7] Guery L and Hugues S (2015). Th17 cell plasticity and functions in cancer immunity. *Biomed Res Int* **2015**314620.
[8] Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, and Stockinger B (2006). TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. *Immunity* **24**, 179–189.
[9] Kolls JK and Linden A (2004). Interleukin-17 family members and inflammation. *Immunity* **21**, 467–476.
[10] Prabhda RH, Fulciniti M, Pelluru D, Rashid N, Nigroiu A, and Nanjappa P, et al (2016). Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma. *Leukemia* **30**, 379–389.
[11] Shen CJ, Yuan ZH, Liu YY, and Hu GY (2012). Increased numbers of T helper 17 cells and the correlation with clinicopathological characteristics in multiple myeloma. *J Int Med Res* **40**, 556–564.
[12] Liu D and Mamorska-Dyga A (2017). Syk inhibitors in clinical development for hematological malignancies. *J Hematol Oncol* **10**, 145.
[13] Ma TK, McAdoo SP, and Tam FW (2016). Spleen tyrosine kinase: a crucial player and potential therapeutic target in renal disease. *Nephron* **133**, 261–269.
[14] Lin YC, Huang DY, Chu CL, Lin YL, and Lin WW (2013). The tyrosine kinase Syk differentially regulates Toll-like receptor signaling downstream of the adaptot molecules TRAF6 and TRAF3. *Sci Signal* **6**, ra71.
[15] Takada Y and Aggarwal BB (2004). TNF activates Syk protein tyrosine kinase leading to TNF-induced MAPK activation, NF-kappaB activation, and apoptosis. *J Immunol* **173**, 1066–1077.
[16] Koerber RM, Held SAE, Heine A, Korthoff P, Daecke SN, and Bringmann A, et al (2015). Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma. *Exp Hematol Oncol* **4**, 21.
[17] Baudot AD, Jeandel PY, Mouska X, Maurer U, Tartare-Deckert S, and Raynaud SD, et al (2009). The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. *Oncogene* **28**, 3261–3273.
[18] Lorenz J, Waldschmidt J, Wilder D, Follo M, Ihorst G, and Chatterjee M, et al (2016). From CILI to multiple myeloma—spleen tyrosine kinase (SYK) influences multiple myeloma cell survival and migration. *Br J Haematol* **174**, 985–989.
[19] Liu C, Qian W, Qian Y, Giliat NY, Lu Y, and Swaidani S, et al (2009). Act1, a U-box E3 ubiquitin ligase for IL-17 signaling. *Sci Signal* **2**, ra63.
[20] Wu NL, Huang DY, Tsou HN, Lin YC, and Lin WW (2015). Syk mediates IL-17-induced CCL20 expression by targeting Act1-dependent K63-linked ubiquitination of TRAF6. *J Invest Dermatol* **135**, 490–498.
[21] Huang W, Thomas B, Flynn RA, Gavey SJ, Wu L, and Kim SV, et al (2015). DIX5 and its associated IncRNA Rnmp modulate TH17 cell effector functions. *Nature* **528**, 517–522.
[22] Laubach JP, Moreau P, San-Miguel JF, and Richardson PG (2015). Panobinostat for the treatment of multiple myeloma. *Clin Cancer Res* **21**, 4767–4773.
[23] Pratt G, Goodyear O, and Moss P (2007). Immunodeficiency and immunotherapy in multiple myeloma. *Br J Haematol* **138**, 563–579.
[24] McGauchy MJ and Cua DJ (2008). Th17 cell differentiation: the long and winding road. *Immunology* **28**, 445–453.
[25] Singh TP, Huettnner B, Koeferl H, Mayer G, Bambach I, and Wallbrecht K, et al (2011). Platelet-activating factor knockdown inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.TGF-beta1 transgenic mice. *Am J Pathol* **178**, 699–708.
[26] Fan X, Wang J, Liu H, Xu R, Ding R, and Jiang S, et al (2015). TRAF6 is required for BLyS-mediated NF-kappaB signaling in multiple myeloma cells. *Med Oncol* **32**, 239.
[27] Sonder SU, Saret S, Tang W, Stundevant DE, Porcella SF, and Siebenlist U (2011). IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms. *J Biol Chem* **286**, 12881–12890.
[28] Gehlert RL (2014). Getting Syk: spleen tyrosine kinase as a therapeutic target. *Trends Pharmacol Sci* **35**, 414–422.
[29] Lucas MC and Tan SL (2014). Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations? *Future Med Chem* **6**, 1811–1827.
[30] Liu H, Tamashiro S, Baritaki S, Penichet M, Yu Y, and Chen H, et al (2012). TRAF6 activation in multiple myeloma: a potential therapeutic target. *Clin Lymphoma Myeloma Leuk* **12**, 155–165.